9部门：鼓励创新药等药品进零售药店销售渠道，创新药ETF（159992）涨超1%，昨日“吸金”2.4亿元

Group 1 - The A-share market saw all three major indices rise collectively, with the CSI Innovation Drug Industry Index increasing by 1.37%, driven by significant gains in stocks such as Zhaoyan New Drug, which rose over 5% [1] - The Innovation Drug ETF (159992) also experienced a rise of 1.17%, with a trading volume exceeding 150 million yuan, indicating active trading [1] - The ETF has recorded a net inflow of 240 million yuan on the previous trading day (January 22), marking five consecutive days of net inflows totaling 860 million yuan, with a latest circulation size of 14.87 billion yuan [1] Group 2 - The Ministry of Commerce and eight other departments released opinions to promote high-quality development in the pharmaceutical retail industry, advocating for deep cooperation between pharmaceutical manufacturers and large distribution companies [2] - The new policies encourage the sale of innovative drugs and reference preparations through retail pharmacies and promote the use of data interfaces by e-commerce platforms to enhance price monitoring [2] - Jianghai Securities noted that the global biopharmaceutical investment environment is gradually improving, with Chinese innovative drug companies increasingly pursuing international collaborations, evidenced by five new licensing agreements in the first week of the new year [2]